Prophylactic administration of urinary trypsin inhibitor prevents postoperative i lypcramylasemia after R2 gastrectomy in patients with gastric cancer a prospective randomized trial

D. Korenaga, H. Orita, Y. Kakeji, M. Haraguchi, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this prospective randomized study was to determine whether prophylactic administration of urinary trypsin inhibitor prevents postoperative damage to the pancreas caused by R2 gastrectomy in patients with gastric cancer, by analyzing related enzyme activities. Among the 22 patients who underwent distal partial gastrectomy together with R2 lymphadenectomy, 12 were given the drug for 3 days postoperatively, and 10 no therapeutic agent. These groups were otherwise comparable. Postoperatively, the control patients had significantly higher levels of total amylase activity in the serum and P-type amylase when compared to the preoperative data. These amylase activities almost remained at the preoperative level in those given the drug. When the ratio of increase in enzyme activities (postoperative value divided by preoperative value) were compared, on the 7th postoperative day, total amylase activity in the serum and P-type amylase were significantly different between the two groups (p < 0.05). This difference was also evident when comparing total amylase activity in the urine (p < 0.05). These findings indicate that prophylactic administration of urinary trypsin inhibitor would aid in preventing postoperative hyperamy-lasemia caused by R2 gastrectomy in patients with gastric cancer.

Original languageEnglish
Pages (from-to)214-221
Number of pages8
JournalEuropean Surgical Research
Volume23
Issue number3-4
DOIs
Publication statusPublished - Jan 1 1991

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint Dive into the research topics of 'Prophylactic administration of urinary trypsin inhibitor prevents postoperative i lypcramylasemia after R2 gastrectomy in patients with gastric cancer a prospective randomized trial'. Together they form a unique fingerprint.

  • Cite this